This article needs additional citations for verification. (August 2019) (Learn how and when to remove this template message)
WuXi Biologics is a Chinese headquartered organization that provides open-access, integrated technology platforms for biologics drug development. WuXi Biologics’ roots date back to 2010 when it was established as a business unit of WuXi AppTec, began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. Since then, WuXi Biologics has focused on establishing state-of-the-art research and manufacturing facilities and building partnerships with pharmaceutical and biotech companies in the space. WuXi Biologics ultimately spun out of WuXi AppTec in 2015 and two years later went public on the Hong Kong Stock Exchange in June of 2017.
Dundalk, Ireland Facility
In April of 2018, WuXi Biologics announced plans to build a new biologics drug substance manufacturing facility on 26 hectares in Dundalk, Ireland. The project is directly supported by the Irish Government through IDA Ireland, with a cost of approximately $394 million. When completed, the facility will be one of the world's largest plants supporting single-use bioreactors and will help accelerate the development of biologic drugs in Europe. 
- "CHNA ETF Video Series: WuXi Biologics". loncarfunds.com. Retrieved 2019-08-14.
- "UPDATE 2-WuXi Biologics prices HK IPO at top as investors seek..." Reuters. 2017-06-06. Retrieved 2019-08-14.
- "WuXi Biologics' Biologics Manufacturing Facility, Dundalk, Ireland". Pharmaceutical Technology. Retrieved 2019-08-14.
- "Jacobs Wins Contract to Provide Construction Services for WuXi". GEN - Genetic Engineering and Biotechnology News. 2019-06-10. Retrieved 2019-08-14.